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Effects of diazoxide in multiple sclerosis
A randomized, double-blind phase 2 clinical trial
ABSTRACT
Objective: The aim of this study was to test the safety of diazoxide and to search for signs of effi-
cacy in patients with relapsing-remitting multiple sclerosis (RRMS).
Methods: In this multicenter, randomized, placebo-controlled, double-blind trial (treatment alloca-
tion was concealed), 102 patients with RRMS were randomized to receive a daily oral dose of
diazoxide (0.3 and 4 mg/d) or placebo for 24 weeks (NCT01428726). The primary endpoint
was the cumulative number of new T1 gadolinium-enhancing lesions per patient, recorded every
4 weeks from week 4 to week 24. Secondary endpoints included brain MRI variables such as the
number of new/enlarging T2 lesions and the percentage brain volume change (PBVC); clinical var-
iables such as the percentage of relapse-free patients, relapse rate, and change in the Expanded
Disability Status Scale score; and safety and tolerability.
Results: Diazoxidewaswell-tolerated and it produced no serious adverse events other than 1 case of
Hashimoto disease. At the 2 doses tested, diazoxide did not improve the primary endpoint or theMRI
and clinical variables related to the presence of new lesions or relapses. Patients treated with diaz-
oxide showed reduced PBVCcomparedwith the placebo group, although such changes could be con-
founded by the higher disease activity of the treated group and the vascular effects of diazoxide.
Conclusion: At the doses tested, oral diazoxide did not decrease the appearance of new lesions evi-
dent by MRI. The effects in slowing the progression of brain atrophy require further validation.
Classification of evidence: This study providesClass I evidence that for patientswith RRMS, diazoxide
(0.3 and 4 mg/d) does not significantly change the number of new MRI T1 gadolinium-enhancing
lesions. Neurol Neuroimmunol Neuroinflamm 2015;2:e147; doi: 10.1212/NXI.0000000000000147
GLOSSARY
AE 5 adverse event; BBB 5 blood-brain barrier; CUAL 5 cumulative unique active lesion; EAE 5 experimental autoimmune
encephalomyelitis; EDSS 5 Expanded Disability Status Scale; Gad1 5 gadolinium-enhancing; ITT 5 intention-to-treat;
KATP 5 ATP-sensitive K1; MS 5 multiple sclerosis; PBVC 5 percentage brain volume change; PP 5 per-protocol;
RRMS 5 relapsing-remitting MS; SF-36 5 Short Form 36 Health Survey.
Diazoxide activates ATP-sensitive K1 (KATP) channels in the smooth musculature of blood
vessels and in pancreatic b-cells, increasing the concentration of glucose in the plasma and pro-
ducing a fall in blood pressure through a vasodilator effect on the arterioles and a reduction in
peripheral resistance.1 Accordingly, diazoxide has been approved for the treatment of malignant
hypertension and hypoglycemia in Europe and the United States. In addition, diazoxide displays
high affinity for KATP channels in the inner mitochondrial membrane, and most of its
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cytoprotective and neuroprotective properties
have been associated with mitochondrial-
targeted preconditioning.2,3
It was recently noted that low doses of diazox-
ide ameliorate the clinical signs of experimental
autoimmune encephalomyelitis (EAE). Diazox-
ide inhibits microglial activation, preventing
neuronal and axonal damage, and induces the
expression, activation, and nuclear translocation
of nuclear factor (erythroid-derived 2)-related
factor 2.4,5 Diazoxide is an orally administered
drug with a good safety profile and well-known
pharmacologic properties, having been on the
market for many years. Thus, diazoxide could
represent a new treatment option for multiple
sclerosis (MS).
Given that microglia play a key role in the
functioning and opening of the blood-brain bar-
rier (BBB),6 and considering the modulation of
microglia activation by diazoxide, we hypothe-
sized that this drug may also modulate the open-
ing of the BBB. If this were the case, it would be
feasible to measure its efficacy by monitoring the
presence of gadolinium-enhancing (Gad1) le-
sions, an endpoint extensively validated in pre-
vious clinical trials.
METHODS Patients. Men and women aged 18–55 years with
relapsing-remitting MS (RRMS, McDonald criteria 20107) and an
Expanded Disability Status Scale (EDSS) score of 0–5.0 were eligible
for this study. The inclusion criteria required at least 1 relapse in the
previous 2 years or the presence of at least 1 Gad1 lesion in the
previous 1 year. The exclusion criteria were (1) patients who are
candidates for treatment with drugs modifying the course of the
disease according to the criteria of the regulatory agencies in each
country, unless the patient refused to initiate such therapy or decided
to postpone the start of this therapy; (2) patients who experienced a
relapse in the 30-day period prior to the baseline visit; (3) patients
on treatment with diazoxide; (4) patients with a medical condition
such as hypotension, insulinoma, hyperuricemia, or diabetes defined
by American Diabetes Association criteria; (5) patients with other
conditions, including drug abuse, liver transplantation, inability to
provide informed consent, or inability to perform all the procedures
in the clinical trial; (6) patients with contraindications for MRI studies;
(7) patients with contraindications for treatment with diazoxide,
excipients, or gadolinium-based agents; (8) patients on corticosteroid
therapy in the last month; (9) patients on interferon b or glatiramer
acetate therapy in the past 3 months; (10) patients on natalizumab
or fingolimod therapy in the past 6 months; (11) patients treated
with chemotherapy (mitoxantrone, azathioprine, cyclophosphamide,
cladribine, methotrexate) or who entered previous trials of treatments
under development; and (12) patients with a positive pregnancy test,
those currently breast-feeding, or women of childbearing potential not
using highly effective methods of contraception.
Standard protocol approvals, registrations, and patient
consents. The trial was approved by the local institutional review
board at each center and by the Spanish and German medical
agencies. Patients were included after providing their informed
consent.
Study design. This was a double-blind, placebo-controlled,
multicenter phase 2a study to determine the safety of diazoxide and
to search for evidence of efficacy of 2 doses of diazoxide in patients
with RRMS (ClinicalTrials.gov: NCT01428726; EUDRA-CT:
2010-023048-34). The trial was conducted at 16 sites (13 in Spain
and 3 in Germany) in accordance with the Helsinki Declaration8 and
adhering to the International Conference on Harmonization
Guidelines for Good Clinical Practice.9 All investigators and patients
were blinded to the treatment and to the blood glucose and diazoxide
levels, unless they were alerted for safety reasons. Diazoxide and
placebo were prepared as identical tablets with no differences in
taste or appearance.
One hundred two patients were randomly assigned to 3 groups:
diazoxide 0.3 mg/d, diazoxide 4mg/d, or placebo (ratio 1:1:1) admin-
istered orally once daily. Block randomization was performed using 2
blocks of 6 elements with random sequences of the 3 arms in each
center using a randomization seed in order to ensure its reproducibil-
ity and using SPSS v17 software and macro Generation of Random
Sequences (!RNDSEQ).
Doses were selected on the basis of preclinical studies in an
animal model of MS4,5 in order to maintain the doses below those
at which diazoxide induces hyperglycemia or hypotension (100
mg/kg/d). Patients received diazoxide in 1 daily oral dose of
0.3 mg or 4 mg (total dose) from day 1 to the end of week 24.
Study visits took place at screening, at baseline, on day 1 (ran-
domization), and every 4 weeks until the end of the 24-week
treatment period or drug discontinuation. Treatment allocation
was concealed without breaking the blinding until the end of the
study. At the end of the follow-up, the patients could enroll in an
additional 24-week observation period.
Confirmed relapse was defined as the occurrence of new symp-
toms or a worsening of previously stable or improving symptoms
and signs lasting more than 24 hours, not associated with fever,
and accompanied by an increase of at least half a point on the
EDSS. When warranted, relapses were managed by the treating
physician according to a standardized scheme: IV administration
of up to 1,000 mg of methylprednisolone per day for 3–5 days.
For the duration of the methylprednisolone therapy, glycemia was
monitored daily using a glucose finger prick test. Diazoxide treat-
ment was maintained during the relapses and the study schedule
was not changed (the visit and MRI schedule remained unaltered)
unless patients needed to use prohibited concomitant treatments.
EDSS was assessed by an independent neurologist not involved in
patient care at screening, at baseline, every 4 weeks, and at
unscheduled visits in the case of MS relapse.
MRI. MRI scans were performed at baseline and every 4 weeks until
the end of the study (week 24). Patients enrolled in the follow-up
study were subjected to an additional scan at week 48. Patients
received a double dose of the contrast agent (0.2 mmol/kg), and
the same agent was used for all patients at the same center, with a
latency of 10 minutes. New and enhancing lesions were identified
by certified radiologists, and T1 and T2 lesion volumes were
determined by trained technicians using the Jim software (Xinapse
Limited Systems, Aldwincle, UK). The normalized brain volume
at baseline and the percentage brain volume change (PBVC)
between baseline and month 24 were calculated using the
Structural Image Evaluation using Normalization of Atrophy
program.10 Black holes were defined as areas of unequivocal low
signal intensity compared with normal-appearing white matter that
did not show contrast uptake and were concordant with a
hyperintense lesion seen on T2-weighted imaging. Finally,
exploratory tissue-type segmentation was used to calculate separate
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estimates of gray matter, white matter, and CSF volumes with
Statistical Parametric Mapping (SPM5). MRI analysis was
performed at the MRI unit of the “Centro de Esclerosis Múltiple
de Cataluña” (Cemcat), Hospital Vall d’Hebron, Barcelona, Spain.
Study endpoints. The primary efficacy endpoint was the cumula-
tive number of new Gad1 lesions on T1-weighted sequences from
week 4–24. We selected this endpoint based on the effects of
diazoxide on microglia activation and closing of the BBB and
because this endpoint has been validated in many previous short-
duration trials (6 months). Secondary MRI endpoints were
cumulative number of new/enlarged lesions on T2-weighted
sequences for all MRIs; cumulative number of new/increased
lesions on T2-weighted sequences in the 6 months after starting
therapy (compared with the baseline MRI); cumulative number of
combined unique active lesions (CUALs), addition of new or
enlarged lesions on T2-weighted sequences that do not enhance
with gadolinium and new Gad1 lesions for all MRIs; cumulative
number of CUALs, addition of new or enlarged lesions on
T2-weighted sequences that do not enhance with gadolinium and
new Gad1 lesions in the 6 months after starting therapy (compared
with the baselineMRI); number of patients without Gad1 lesions in
T1-weighted sequences in the 6 months after starting therapy; and
PBVC. Secondary clinical endpoints were relapse-free status, relapse
rate, number of relapses requiring corticosteroid treatment, time to
first relapse during the trial, change in EDSS, and quality of life
assessed with the Short Form 36 Health Survey (SF-36). Secondary
safety endpoints were incidence, nature, and severity of adverse events
(AEs) during the 6 months of therapy up until 15 days after the last
dose of diazoxide or placebo, including control of glucose levels,
glycated hemoglobin, blood pressure, and presence of hirsutism.
Statistical analysis. The primary alternate hypothesis was that
the cumulative number of new T1 Gad1 lesions observed in
all MRIs would be distinct in patients treated with diazoxide
(0.3 or 4 mg/d) and those who received placebo. The null hypoth-
esis was tested in a negative binomial regression model, as we con-
sidered this to best explain the distribution of new Gad1 lesions.11
The analysis was planned for an intention-to-treat (ITT) population
(any patient who was randomized, received treatment, and had at
least 1 postbaseline efficacy variable completed) and a per-protocol
(PP) population (any patient who was randomized and received the
protocol-required treatment and processing). In the PP population,
no data input methods were used. In the ITT population, when
primary outcome observations were missing in the study visits, the
patient was assigned the median of the number of new lesions for
the remaining visits.
The univariate analysis of categorical variables involved the x2
or Fisher exact test, and continuous variables were assessed with a
t test, a Mann-Whitney test, or a Wilcoxon test, as appropriate.
Differences in the number of new T2 lesions and CUALs were
analyzed using the negative binomial distribution, as described pre-
viously.11 Paired samples with continuous variables were analyzed
using a t test or Wilcoxon signed-rank test. The time-to-event anal-
ysis was achieved with a Cox analysis. Multivariate analysis was
performed with linear generalized models or generalized estimating
equations with the evolution between visits as an outcome measure.
p Values #0.05 were considered significant in all tests, which were
carried out with the SAS statistical package v9.2.
The underlying assumption for calculating the sample size
was a minimum effect between groups of 2 lesions and a common
SD of 2.55.12 We assumed a power of 80% and an a error of
0.025. Sample size estimation was based on the t test. We took
into account that endpoint assessment would be performed after a
6-month follow-up, so we estimated a loss rate of 10%. Finally,
the study sample size was calculated with GRANMO 7.10 soft-
ware, which indicated that 35 patients were needed in each group
(a total of 105 patients) to detect a treatment effect $2 lesions
with a common SD of 2.55 and a loss rate of 10%.
Primary research questions and classification of evidence.
The aim of this study was to test the safety of diazoxide and to search
for signs of efficacy in patients with RRMS. This study provides
Class I evidence that diazoxide is safe and well-tolerated in patients
with MS. It does not decrease the presence of new lesions on
MRI and it slows the progression of brain atrophy.
RESULTS Description of the cohort. Of the 119 pa-
tients screened between June 2011 and March 2013,
102 were randomized to receive diazoxide (0.3 or 4
mg) or the placebo orally once daily (the patient distribu-
tion is shown in the figure). In the 2 groups that received
diazoxide, 5.9% (0.3 mg) and 13.9% (4 mg) of patients
prematurely discontinued the treatment, compared with
12.1% of the patients who received placebo. Double-
blinding was maintained until the end of the study. The
demographic and baseline disease characteristics were
generally similar in each treatment group (table 1).
Efficacy for the MRI and clinical outcomes. In the diaz-
oxide groups, we found no differences in the primary
endpoint in the ITT or PP analysis (mean cumulative
number of new T1 Gad1 lesions at week 24) or in
the other MRI variables associated with the presence of
new lesions (cumulative number of new/enlarged lesions
in T2-weighted sequences for all MRIs, cumulative
number of new/increased lesions on T2-weighted
sequences in the 6 months after starting therapy
Figure Patient distribution flowchart
ITT 5 intention-to-treat; PP 5 per-protocol; SAE 5 serious adverse event.
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compared with the baseline MRI, cumulative number of
CUALs, and number of patients without lesions in
Gad1 T1-weighted sequences in the 6 months after
starting therapy; table 2). We found a decrease in the
PBVC in the patients who received diazoxide compared
with placebo (0.3 mg arm: 20.1 [SD 0.76], p 5
0.0104; 4 mg arm: 0.02 [SD 0.60], p 5 0.0124;
placebo arm: 20.39 [SD 0.54]). The number of new
T2/Proton Density lesions converting to black holes was
not different between arms (diazoxide 4 mg arm: 0.06%
[SD 0.22]; diazoxide 0.3 mg arm: 0.11% [SD 0.18];
placebo arm: 0.17% [SD 0.50]; Kruskal-Wallis test,
p 5 0.32). As expected in light of the small sample
size of this trial, we found no differences in the clinical
variables of relapse-free status, relapse rate, number of
relapses requiring corticosteroid treatment, time to first
relapse during the trial, change in EDSS, or quality of life
(SF-36) (table 2).
Safety and tolerability. There were 6 serious AEs dur-
ing the study, 3 of which were considered to be
severe: biliary colic, pregnancy (severe), fracture of
the left radius, duodenal ulcer (severe), acute autoim-
mune hypothyroidism, reduced libido (severe), and
fracture of the left clavicle (table 3). All AEs occurred
in patients receiving diazoxide, except for the patient
who reported reduced libido, who received placebo.
Only autoimmune hypothyroidism was considered to
be related to the therapy, and therapy was discontin-
ued only in the case of concurrent pregnancy. Regard-
ing the AEs specifically related to the known clinical
effects of diazoxide, such as hyperglycemia or hypo-
tension, glucose levels always remained within the
limits of normality, confirming that the doses of the
drug used were lower than those that induce hyper-
glycemic and hypotensive effects.
DISCUSSION In this study we evaluated the effects of
oral diazoxide in preventing disease activity and tissue
damage in RRMS as assessed byMRI. Diazoxide is a po-
tassium channel opener, and preclinical research shows
that at very low doses it can modulate microglia activa-
tion and produce protective effects in animal models
of MS.4,5 Although the action of diazoxide on microglia
would be sufficient to explain the improvements
observed in EAE mice after diazoxide treatment, the
presence of functional KATP channels in other glial cells
and neurons could explain any additional benefits in the
CNS produced by the drug.13–17 These studies also sug-
gest that diazoxide could produce neuroprotection
through different mechanisms depending on the drug
concentration and due to its selective activation of mito-
KATP channels.5,18–20 Multiple mechanisms could
contribute to demyelination and neuroaxonal injury in
Table 1 Demographics of the cohort at baseline (ITT population)
Diazoxide 0.3 mg/d Diazoxide 4 mg/d Placebo p Value
n 34 35 33
Age, y, mean 6 SD 41.3 6 6.9 41.0 6 7.4 42.4 6 7.6 NS
Sex, M/F 9/25 15/20 7/26 ,0.05
No. previous relapses within past 2 y,
mean 6 SD
1.3 6 0.52 1.5 6 1.28 1.3 6 0.48 NS
EDSS score, median (range) 1.5 (0–5.0) 1.5 (0–5.0) 2.0 (0–4.0) NS
Previous DMD, Y/N 12/22 13/22 9/24 ,0.05
No. T2 lesions 58.4 6 37.04 (45.3–71.6) 68.8 6 62.16 (47.4–90.2) 55.9 6 44.11 (40.2–71.5) NS
Volume T2 lesions, cm3 6,856.6 6 11,199
(2,885.5–10,828)
6,278.7 6 6,663.4
(3,989.8–8,567.7)
5,461.5 6 6,694.6
(3,087.7–7,835.3)
,0.05
No. Gad1 lesions 1.5 6 2.33 (0.7–2.3) 1.4 6 2.25 (0.6–2.1) 1.1 6 1.88 (0.4–1.8) NS
NBV 1,047,831 6 52,645
(1,028,850–1,066,811)
1,034,549 6 59,387
(1,013,138–1,055,960)
1,043,200 6 56,874
(1,021,566–1,064,834)
NS
Volume black holes, cm3 564.45 6 716.106
(268.86–860.05)
832.82 6 1,309.819
(279.73–1,385.91)
1,066.14 6 1,578.976
(366.06–1,766.22)
,0.05
No. black holes, n (%)
0 5 (14.71) 7 (20.00) 8 (24.24) NS
1–5 14 (41.10) 14 (40.01) 13 (39.39) NS
6–10 8 (23.53) 6 (17.14) 4 (12.12) ,0.05
11–20 3 (8.82) 3 (8.57) 3 (9.09) NS
>20 1 (2.94) 1 (2.86) 2 (6.06) NS
Abbreviations: DMD 5 disease-modifying drugs; EDSS 5 Expanded Disability Status Scale; Gad1 5 gadolinium-enhancing; ITT 5 intention-to-treat;
NBV 5 normalized brain volume; NS 5 not significant.
Unless otherwise indicated, data are expressed as mean 6 SD (range).
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MS.21,22 It has been postulated that chronic microglial
activation is partially responsible for the damage to the
CNS during attacks, as well as between attacks,
contributing to disease progression.23,24 For this reason,
downmodulating chronic microglia activation may
prevent CNS damage during acute MS relapses, as well
as in the progressive phases. Also, it has been shown that
mito-KATP activation by diazoxide prevents neuronal
oxidative stress and excitotoxic cell death, whereas at
the mitochondrial level it can activate defense and
antiapoptotic mechanisms.2,25
Considering diazoxide has been on the market for
decades and has an excellent safety profile, we evalu-
ated the efficacy of low doses of diazoxide in RRMS.
The objective of the trial was to obtain preliminary evi-
dence of efficacy using the cumulative number of new
T1 Gad1 lesions as a surrogate endpoint. This end-
point was selected because it is a sensitive endpoint in
clinical trials with immunomodulatory drugs for
RRMS with strong validation in many previous trials.
The evidence that the modulation of microglia affects
the integrity of the BBB and the development of
parenchymal lesions6 suggested that this endpoint
might be sensitive to the effects of diazoxide. In addi-
tion, the trial included secondary endpoints that are
more specifically related to neuroprotection and micro-
glial modulation, such as the prevention of brain vol-
ume loss (brain atrophy) or the development of black
holes. Regarding the primary endpoint, we found no
differences between groups with a negative binomial
distribution,11 and the treated group had higher activity.
Even if patients were randomly distributed, the group
receiving diazoxide started the trial with higher disease
activity in terms of the number of Gad1 lesions than
the placebo group. This higher activity in the treated
group was maintained throughout the trial. Therefore,
our interpretation is that the treated group was a more
active group than the placebo group, which explains the
differences between groups in increasing the number of
contrast-enhancing lesions better than a true effect of
the drug. Thus, we conclude that at the dose tested,
diazoxide does not seem to have a significant effect that
impedes the appearance of new Gad1 lesions.
Regarding the effects on brain atrophy, we found
that the PBVC progressed more slowly in patients
who received diazoxide and in those on the higher dose.
These findings are consistent with a recent study report-
ing the validity of brain atrophy measurement as an out-
come measure for phase 2 trials in RRMS.26 However,
the atrophy effects observed may also be secondary to
fluid shifts and not true protection against brain injury,
considering the fact that the treated group had more
active disease and the vasodilator effects and the effects
on peripheral resistance displayed by diazoxide.
This study indicates that diazoxide is a safe drug
that is well-tolerated in patients with MS, but we
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did not find evidence of efficacy in preventing forma-
tion of new inflammatory lesions. The question
regarding whether diazoxide prevents brain atrophy
requires further study.
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